Increased apolipoprotein A5 expression in human and rat non-alcoholic fatty livers

Pathology

Volumn 47, Issue 4, 2015, Pages 341-348

  Feng, Qin ^a,b   Baker, Susan S ^b   Liu, Wensheng ^b   Arbizu, Ricardo A ^b   Aljomah, Ghanim ^b   Khatib, Maan ^b   Nugent, Colleen A ^b   Baker, Robert D ^b   Forte, Trudy M ^a,c   Hu, Yiyang ^a   Zhu, Lixin ^a,b  

^a SHANGHAI UNIVERSITY OF TRADITIONAL CHINESE MEDICINE   (China)

^b UNIVERSITY AT BUFFALO   (United States)

^c CHILDREN S HOSPITAL OAKLAND RESEARCH INSTITUTE   (United States)

Author keywords

apoA5; NAFLD; NASH; perilipin; triglyceride

Indexed keywords

APOA5 PROTEIN, HUMAN; APOA5 PROTEIN, RAT; APOLIPOPROTEIN; APOLIPOPROTEIN A; APOLIPOPROTEIN A5;

ADOLESCENT; ANIMAL; BIOSYNTHESIS; CHILD; DNA MICROARRAY; FEMALE; HEP-G2 CELL LINE; HUMAN; MALE; METABOLISM; NONALCOHOLIC FATTY LIVER; PATHOLOGY; RAT; REAL TIME POLYMERASE CHAIN REACTION; SPRAGUE DAWLEY RAT; WESTERN BLOTTING;

ADOLESCENT; ANIMALS; APOLIPOPROTEIN A-V; APOLIPOPROTEINS; APOLIPOPROTEINS A; BLOTTING, WESTERN; CHILD; FEMALE; HEP G2 CELLS; HUMANS; MALE; NON-ALCOHOLIC FATTY LIVER DISEASE; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; RATS; RATS, SPRAGUE-DAWLEY; REAL-TIME POLYMERASE CHAIN REACTION;

EID: 84978761875     PISSN: 00313025     EISSN: 14653931     Source Type: Journal    
DOI: 10.1097/PAT.0000000000000251     Document Type: Article

References (51)

1. 1. O'Brien, P.J., Alborn, W.E., Sloan, J.H., et al. The novel apolipoprotein A5 is presentin human serum, is associated with VLDL, HDL, and chylomicrons, and circulates at very low concentrations compared with other apolipo-proteins. Clin Chem 51 (2005), 351–359.
2. 2. Pennacchio, L.A., Olivier, M., Hubacek, J.A., et al. An apolipoprotein influencing triglycerides in humans and mice revealed by comparative sequencing. Science 294 (2001), 169–173.
3. 3. Lookene, A., Beckstead, J.A., Nilsson, S., et al. Apolipoprotein A-V-heparin interactions: implications for plasma lipoprotein metabolism. J Biol Chem 280 (2005), 25383–25387.
4. 4. Shu, X., Nelbach, L., Weinstein, M.M., et al. Intravenous injection of apoli-poprotein A-V reconstituted high-density lipoprotein decreases hypertri-glyceridemia in apoav-/- mice and requires glycosylphosphatidylinositol-anchored high-density lipoprotein-binding protein 1. Arterioscler Thromb Vasc Biol 30 (2010), 2504–2509.
5. 5. Schaap, F.G., Rensen, P.C., Voshol, P.J., et al. ApoAV reduces plasma triglycer-ides by inhibiting very low density lipoprotein-triglyceride (VLDL-TG) production and stimulating lipoprotein lipase-mediated VLDL-TG hydrolysis. J Biol Chem 279 (2004), 27941–27947.
6. 6. Shu, X., Nelbach, L., Ryan, R.O., et al. Apolipoprotein A-V associates with intrahepatic lipid droplets and influences triglyceride accumulation. Bio-chim Biophys Acta 2010 (1801), 605–608.
7. 7. Blade, A.M., Fabritius, M.A., Hou, L., et al. Biogenesis of apolipoprotein A-V and its impact on VLDL triglyceride secretion. J Lipid Res 52 (2011), 237–244.
8. 8. Shu, X., Chan, J., Ryan, R.O., et al. Apolipoprotein A-V association with intracellular lipid droplets. J Lipid Res 48 (2007), 1445–1450.
9. 9. Shu, X., Ryan, R.O., Forte, TM., Intracellular lipid droplet targeting by apolipoprotein A-V requires the carboxyl-terminal segment. J Lipid Res 49 (2008), 1670–1676.
10. 10. van der Vliet, H.N., Sammels, M.G., Leegwater, A.C., et al. Apolipoprotein A-V: a novel apolipoprotein associated with an early phase of liver regeneration. J Biol Chem 276 (2001), 44512–44520.
11. 11. Tijburg, L.B., Nyathi, C.B., Meijer, G.W., et al. Biosynthesis and secretion of triacylglycerol in rat liver after partial hepatectomy. J Biol Chem 277 (1991), 723–728.
12. 12. Farrell, GC., Probing Prometheus: fat fueling the fire?. Hepatology 40 (2004), 1252–1255.
13. 13. Pennacchio, L.A., Olivier, M., Hubacek, J.A., et al. Two independent apolipo-protein A5 haplotypes influence human plasma triglyceride levels. Hum Mol Genet 11 (2002), 3031–3038.
14. 14. Palmen, J., Smith, A.J., Dorfmeister, B., et al. The functional interaction on in vitro gene expression of APOA5 SNPs, defining haplotype APOA52, and their paradoxical association with plasma triglyceride but not plasma apoAV levels. Biochim Biophys Acta 2008 (1782), 447–452.
15. 15. Talmud, P.J., Palmen, J., Putt, W., et al. Determination of the functionality of common APOA5 polymorphisms. J Biol Chem 280 (2005), 28215–28220.
16. 16. Pullinger, C.R., Aouizerat, B.E., Movsesyan, I., et al. An apolipoprotein A-V gene SNP is associated with marked hypertriglyceridemia among Asian-American patients. J Lipid Res 49 (2008), 1846–1854.
17. 17. Priore Oliva, C., Pisciotta, L., Li Volti, G., et al. Inherited apolipoprotein A-V deficiency in severe hypertriglyceridemia. Arterioscler Thromb Vasc Biol 25 (2005), 411–417.
18. 18. Albers, K., Schlein, C., Wenner, K., et al. Homozygosity for a partial deletion of apoprotein A-V signal peptide results in intracellular missorting of the protein and chylomicronemia in a breast-fed infant. Atherosclerosis 233 (2014), 97–103.
19. 19. Ogden, C.L., Carroll, M.D., Kit, B.K., et al. Prevalence of childhood and adult obesity in the United States. JAMA 311 (2014), 806–814.
20. 20. Williams, C.D., Stengel, J., Asike, M.I., et al. Prevalence of nonalcoholic fatty liver disease and nonalcoholic steatohepatitis among a largely middle-aged population utilizing ultrasound and liver biopsy: a prospective study. Gastroenterology 140 (2011), 124–131.
21. 21. Welsh, J.A., Karpen, S., Vos, MB., Increasing prevalence of nonalcoholic fatty liver disease among United States adolescents, 1988–1994 to 2007–2010. J Pediatr 162 (2013), 2007–2010.
22. 22. Kleiner, D.E., Brunt, E.M., Van Natta, M., et al. Design and validation of a histological scoring system for nonalcoholic fatty liver disease. Hepatology 41 (2005), 1313–1321.
23. 23. Ress, C., Moschen, A.R., Sausgruber, N., et al. The role of apolipoprotein A5 in non-alcoholic fatty liver disease. Gut 60 (2011), 985–991.
24. 24. Baker, S.S., Baker, R.D., Liu, W., et al. Role of alcohol metabolism in nonalcoholic steatohepatitis. PLoS One, 5, 2010, e9570.
25. 25. Liu, W., Baker, S.S., Baker, R.D., et al. Upregulation of hemoglobin expression by oxidative stress in hepatocytes and its implication in nonalcoholic steatohepatitis. PLoS One, 6, 2011, e24363.
26. 26. Zhu, L., Baker, S.S., Liu, W., et al. Lipid in the livers of adolescents with nonalcoholic steatohepatitis: combined effects of pathways on steatosis. Metabolism 60 (2011), 1001–1011.
27. 27. Moya D, Baker SS, Liu W, et al. Novel pathway for iron deficiency in pediatric non-alcoholic steatohepatitis. Clin Nutr 2014.
28. 28. Desai, S., Baker, S.S., Liu, W., et al. Paraoxonase 1 and oxidative stress in paediatric non-alcoholic steatohepatitis. Liver Int 34 (2014), 110–117.
29. 29. Patel, R., Baker, S.S., Liu, W., et al. Effect of dietary advanced glycation end products on mouse liver. PLoS One, 7, 2012, e35143.
30. 30. Lee, J.M., Okumura, M.J., Davis, M.M., et al. Prevalence and determinants of insulin resistance among US adolescents: a population-based study. Diabetes Care 29 (2006), 2427–2432.
31. 31. Straub, B.K., Stoeffel, P., Heid, H., et al. Differential pattern of lipid droplet-associated proteins and de novo perilipin expression in hepatocyte steato-genesis. Hepatology 47 (2008), 1936–1946.
32. 32. Forte, T.M., Shu, X., Ryan, R.O., The ins (cell) and outs (plasma) of apolipoprotein A-V. J Lipid Res 50 (2009), S150–S155 (Suppl).
33. 33. Merkel, M., Loeffler, B., Kluger, M., et al. Apolipoprotein AV accelerates plasma hydrolysis of triglyceride-rich lipoproteins by interaction with proteoglycan-bound lipoprotein lipase. J Biol Chem 280 (2005), 21553–21560.
34. 34. Nilsson, S.K., Lookene, A., Beckstead, J.A., et al. Apolipoprotein A-V interaction with members of the low density lipoprotein receptor gene family. Biochemistry 46 (2007), 3896–3904.
35. 35. van der Vliet, H.N., Schaap, F.G., Levels, J.H., et al. Adenoviral overexpression of apolipoprotein A-V reduces serum levels of triglycerides and cholesterol in mice. Biochem Biophys Res Commun 295 (2002), 1156–1159.
36. 36. Fruchart-Najib, J., Bauge, E., Niculescu, L.S., et al. Mechanism of triglyceride lowering in mice expressing human apolipoprotein A5. Biochem Biophys Res Commun 319 (2004), 397–404.
37. 37. Baroukh, N., Bauge, E., Akiyama, J., et al. Analysis of apolipoprotein A5, c3, and plasma triglyceride concentrations in genetically engineered mice. Arterioscler Thromb Vasc Biol 24 (2004), 1297–1302.
38. 38. Dallinga-Thie, G.M., van Tol, A., Hattori, H., et al. Plasma apolipoprotein A5 and triglycerides in type 2 diabetes. Diabetologia 49 (2006), 1505–1511.
39. 39. Talmud, P.J., Cooper, J.A., Hattori, H., et al. The apolipoprotein A-V genotype and plasma apolipoprotein A-V and triglyceride levels: prospective risk of type 2 diabetes. Results from the Northwick Park Heart Study II. Diabetologia 49 (2006), 2337–2340.
40. 40. Vaessen, S.F., Schaap, F.G., Kuivenhoven, J.A., et al. Apolipoprotein A-V, triglycerides and risk of coronary artery disease: the prospective Epic-Norfolk Population Study. J Lipid Res 47 (2006), 2064–2070.
41. 41. Henneman, P., Schaap, F.G., Havekes, L.M., et al. Plasma apoAV levels are markedly elevated in severe hypertriglyceridemia and positively correlated with the APOA5 S19W polymorphism. Atherosclerosis 193 (2007), 129–134.
42. 42. Prieur, X., Huby, T., Coste, H., et al. Thyroid hormone regulates the hypo-triglyceridemic gene APOA5. J Biol Chem 280 (2005), 27533–27534.
43. 43. Genoux, A., Dehondt, H., Helleboid-Chapman, A., et al. Transcriptional regulation of apolipoprotein A5 gene expression by the nuclear receptor RORalpha. Arterioscler Thromb Vasc Biol 25 (2005), 1186–1192.
44. 44. Nowak, M., Helleboid-Chapman, A., Jakel, H., et al. Insulin-mediated down-regulation of apolipoprotein A5 gene expression through the phosphatidy-linositol 3-kinase pathway: role of upstream stimulatory factor. Mol Cell Biol 25 (2005), 1537–1548.
45. 45. Jakel, H., Nowak, M., Moitrot, E., et al. The liver X receptor ligand T0901317 down-regulates APOA5 gene expression through activation of SREBP-1c. J Biol Chem 279 (2004), 45462–45469.
46. 46. Tankurt, E., Biberoglu, S., Ellidokuz, E., et al. Hyperinsulinemia and insulin resistance in non-alcoholic steatohepatitis. J Hepatol, 31, 1999, 963.
47. 47. Choudhury, J., Sanyal, AJ., Insulin resistance in NASH. Frontiers Biosci 10 (2005), 1520–1533.
48. 48. Samuel, V.T., Liu, Z.X., Qu, X., et al. Mechanism of hepatic insulin resistance in non-alcoholic fatty liver disease. J Biol Chem 279 (2004), 32345–32353.
49. 49. Eshraghian, A., Hamidian Jahromi, A., Non-alcoholic fatty liver disease and thyroid dysfunction: A systematic review. World J Gastroenterol 20 (2014), 8102–8109.
50. 50. Kang, H.S., Okamoto, K., Takeda, Y., et al. Transcriptional profiling reveals a role for RORalpha in regulating gene expression in obesity-associated inflammation and hepatic steatosis. Physiol Genomics 43 (2011), 818–828.
51. 51. Lima-Cabello, E., Garcia-Mediavilla, M.V., Miquilena-Colina, M.E., et al. Enhanced expression of pro-inflammatory mediators and liver X-recep-tor-regulated lipogenic genes in non-alcoholic fatty liver disease and hepatitis. C. Clin Sci 120 (2011), 239–250.